NFL Biosciences S.A.
ALNFL.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €13,939 | €19,366 | €23,487 | €11,674 |
| - Cash | €2,928 | €1,914 | €3,546 | €2,338 |
| + Debt | €30 | €41 | €53 | €62 |
| Enterprise Value | €11,042 | €17,493 | €19,994 | €9,398 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | – | – | – | – |
| Gross Profit | -€41 | -€41 | -€26 | -€27 |
| % Margin | – | – | – | – |
| EBITDA | -€2,072 | -€1,822 | -€827 | -€1,767 |
| % Margin | – | – | – | – |
| Net Income | -€1,804 | -€1,349 | -€732 | -€1,635 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.14 | -0.14 | -0.075 | -0.2 |
| % Growth | 0% | -85.7% | 62.3% | – |
| Operating Cash Flow | – | – | – | – |
| Capital Expenditures | – | – | – | – |
| Free Cash Flow | – | – | – | – |